Summary: The placebo effect — where expecting relief can produce real pain reduction — is one of medicine’s most intriguing phenomena. A multi-institutional team has now mapped the precise neural pathway that enables this effect, identifying the brain regions and circuits that trigger the brain’s own opioid release to block pain.
Using a “reverse-translation” approach that adapted human placebo procedures for mice, researchers traced a cortical-to-brainstem pathway and pinpointed where the brain releases endogenous opioid peptides (endorphins) to suppress pain signals.
Key Findings
- Broad-Spectrum Relief: Conditioning mice to expect relief from one type of pain (for example, heat) produced resilience that generalized across different pain types, including injury-related inflammatory pain.
- Preemptive Resilience: The results suggest it may be possible to “train” humans before anticipated events — such as surgery — to build natural resistance to post-operative pain through placebo conditioning.
- An Alternative to Opioids: Because placebo analgesia engages the brain’s internal opioid system, it can provide widespread pain relief without the addictive risks or systemic side effects of prescription opioid drugs.
- Cross-Species Validation: The correspondence between mouse and human brain regions supports the use of rodent models to develop behavioral or cognitive training protocols that could translate to chronic pain patients.
Source: UCSD
Placebo responses — relief produced by expectation rather than an active drug — are increasingly recognized as potentially powerful clinical tools for conditions like pain and depression. However, the exact neural mechanisms behind these expectancy-driven effects have been unclear.
A team led by Matthew Banghart, associate professor in the School of Biological Sciences at the University of California San Diego, has now identified the neural circuitry that drives placebo pain relief. Published in Neuron, the study describes the brain regions and pathways that support placebo analgesia and pinpoints where endogenous opioid signaling is essential for that relief.
This work is the first to use a reverse translation strategy: the researchers adapted a human placebo protocol for mice and then used neurotechnological tools to map and manipulate the resulting activity. Collaborators at the University of Pennsylvania and UC Irvine confirmed that the mouse brain regions activated by the protocol correspond to areas implicated in human placebo studies.
By precisely mapping circuits and selectively manipulating neural activity, the team discovered that cortical inputs to the brainstem — specifically projections to the ventrolateral periaqueductal gray (vlPAG) — are essential for placebo-induced pain relief. They showed that vlPAG neurons that project downward into the spinal cord are required for both morphine analgesia and placebo analgesia, while the placebo effect uniquely requires medial prefrontal and anterior cingulate cortical inputs to the vlPAG.
To measure endogenous opioid peptide activity during placebo trials, researchers used novel sensors developed with partners at UC Davis and the Max Planck Florida Institute for Neuroscience. Those sensors detected increased opioid peptide signaling in the vlPAG when animals were conditioned to expect relief.
To test causality, the team used a light-activated version of naloxone (a drug that blocks opioid receptors) created in Banghart’s lab, called PhNX (photoactivatable naloxone). Illumination allowed precise control over when and where opioid signaling was blocked. Using PhNX, they showed that both morphine-induced and placebo-induced analgesia depend on opioid signaling in the vlPAG.
Co-first author Janie Chang-Weinberg, a PhD student in the Biological Sciences Graduate Program, summarized the implication: “We effectively trained the brain to deploy its own broad-spectrum painkillers where needed, avoiding the systemic and addictive risks of externally administered opioids.”
The study’s findings increase the translational relevance of animal placebo models and suggest a strategy for preventive placebo conditioning that could build durable resilience to pain. The researchers plan follow-up studies to investigate how different conditioning protocols shape placebo learning and to identify methods that might translate into clinical practice for people with chronic pain.
“This is a powerful mechanism,” said Banghart. “We should be intentionally harnessing expectancy-driven analgesia to reduce pain and suffering.”
Key Questions Answered:
A: It begins with expectation in the brain, but it produces real, measurable physiological changes. The study demonstrates that expectation triggers endorphin release in brainstem circuits that descend to the spinal cord and block pain signals — a biological mechanism, not mere imagination.
A: That is an intended long-term goal. If conditioning can reliably teach the brain to produce endogenous analgesia on demand, it could reduce dependence on synthetic opioids and other pain medicines. Clinical translation will require careful development of safe, effective conditioning protocols.
A: Training relies on associative conditioning. Repeatedly pairing a distinctive cue or setting with effective pain relief causes the brain to associate that cue with analgesia. Over time, exposure to the cue alone can trigger the brain’s own pain-relief mechanisms, even without an active drug.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by editorial staff.
- Additional explanatory context was added by the newsroom.
About this pain and neurology research news
Author: Mario Aguilera
Source: UCSD
Contact: Mario Aguilera – UCSD
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Top-down control of the descending pain modulatory system drives multimodal placebo analgesia” by Giulia Livrizzi, Janie Chang-Weinberg, Desiree A. Johnson, Susan T. Lubejko, Jingzhu Liao, Blake A. Kimmey, Chunyang Dong, Yuan Li, Kevin T. Beier, Gregory Corder, Lin Tian, and Matthew R. Banghart.
DOI: 10.1016/j.neuron.2026.03.025
Abstract
Top-down control of the descending pain modulatory system drives multimodal placebo analgesia
Placebo analgesia — the suppression of pain through expectation and prior experience with an inert treatment — is a robust clinical phenomenon, yet its causal neural basis has been unresolved. By reverse-translating a human placebo paradigm to mice, this study identifies cortical-to-brainstem circuits that causally mediate placebo pain relief.
Conditioning suppressed both nociceptive and affective-motivational pain behaviors and generalized to pain forms that were not directly conditioned. Descending neurons in the ventrolateral periaqueductal gray (vlPAG) are necessary for both morphine and placebo analgesia, while placebo analgesia additionally requires inputs from the medial prefrontal and anterior cingulate cortices to the vlPAG.
Conditioning enhances stimulus-evoked release of endogenous opioids in the vlPAG, which in turn gates descending pain modulation. Notably, conditioning in pain-naive animals produced lasting placebo analgesia after injury, suggesting a potential translational strategy in which preventive conditioning builds resilience to future pain.